Loading...
•
Jun 30, 2025
•/
BioNTech SE Q2 2025 Earnings Report
BioNTech SE reported a significant revenue increase in Q2 2025, although it continued to post a net loss as it ramped up investment in oncology and strategic acquisitions.
Key Takeaways
Revenues doubled year-over-year driven by COVID-19 vaccine collaboration, but BioNTech still recorded a substantial net loss while progressing its oncology strategy and acquiring CureVac.
Forward Guidance
BioNTech reaffirmed its 2025 guidance with a focus on backend-loaded revenue, supported by ongoing vaccine sales, strategic collaborations, and development milestones.
Positive Outlook
- Revenue guidance maintained at €1.7B–€2.2B for FY2025
- Expected $1.5B upfront cash from BMS in Q3
- Strong cash position of nearly €16B supports continued R&D investments
- Launch preparation for new COVID-19 vaccine underway for 2025–2026 season
- Continued clinical progress across oncology pipeline, including BNT327
Challenges Ahead
- Net loss of €386.6M in Q2 despite increased revenues
- R&D and SG&A expenses remain high
- No positive net income expected for full FY2025
- Dependency on regulatory approvals for vaccine launch timing
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...